MYC and breast carcinoma: Studies in the ER+ breast cancer cell line MCF7 have provided evidence supporting that the c-myc proto-oncogene is modulated by Ca2+ influx through Orai3 by a mechanism including the MAP kinase pathway as Orai3 knockdown results in a reduction in the expression and activity of c-myc, decreased pERK1/2 levels and cell-cycle arrest in G1 phase [36].